Metronidazole 500mg/100ml Solution for Infusion
Sponsors
Pfizer Inc.
Conditions
Blood Stream InfectionComplicated Intra-abdominal InfectionComplicated Urinary Tract InfectionHospital-Acquired PneumoniaHospital-acquired pneumonia or ventilator-associated pneumoniaIntra-abdominal InfectionSepsisSuspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment
Phase 2
C3601008 - A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
RecruitingCTIS2022-501575-12-00
Start: 2023-04-24Target: 20Updated: 2025-10-15
C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment
Not yet recruitingCTIS2023-507757-15-01
Target: 26Updated: 2025-10-21